Nasdaq · Healthcare

Anika Therapeutics, Inc. (ANIK)

As-reported financials and recent SEC filings for Anika Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$112.8M

Net income

$-10.9M

Net margin

-9.6%

Diluted EPS

$-0.76

ROE

-7.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$112.8M	$119.9M	$120.8M	$113.8M	$147.8M
Gross profit	$63.8M	$76.0M	$82.5M	$73.2M	$82.9M
Operating income	$-11.1M	$-5.1M	$844,000	$3.7M	$2.6M
Net income	$-10.9M	$-56.4M	$-82.7M	$-14.9M	$4.1M
Diluted EPS	$-0.76	$-3.83	$-5.64	$-1.02	$0.28

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-23

42026-06-23

42026-06-23

42026-06-23

42026-06-23

8-K2026-06-23

DEFA14A2026-06-08

42026-06-05

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ANIK

Search Anika Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.